16 April 2026 Fresh hire, who will take up his new role in May, brings years of expertise in pharmaceuticals and artificial intelligence to the firm’s Frankfurt practice.
13 April 2026
10 April 2026
Latest Features
Europe
Europe’s latest patent fee increases are modest at the EPO but include a rare steep hike in the UK, forcing applicants to reassess filing routes, portfolio value, and long-term cost strategies, say James Bell and Yelena Morozova.
Asia
The clash between one of India’s largest B2B marketplaces and the country’s drugs regulator challenges the “passive” position of such platforms with regards to allegedly unlawful pharmaceutical listings, says Aarti Aggarwal of Remfry & Sagar.
Europe
After an overwhelmingly positive Supreme Court ruling for companies working in AI, Rachel Free of CMS outlines the necessary practical steps for patent holders—including enforcement of the ‘black box’ tech, the ruling’s influence on the UPC, and how to manage related applications.
Americas
From public use and foreign sales to the challenges of proving infringement, plant patents present unique legal opportunities—and pitfalls—for the agricultural industry, explain Bree Vculek, Gaby Longsworth, and Robert Millonig of Sterne Kessler.
Europe
Traceability and transparency of training practices, and the value of bespoke tool, are among the key AI trends that will be shaped by legal and regulatory developments in 2026, write experts from Rouse.
Europe
A number of ongoing legislative processes are likely to significantly impact the life sciences industry this year, writes Jackie Mulryne of Morgan Lewis.
Europe
The High Court’s ruling clarifies aspects of the SPC waiver but leaves unresolved questions relating to export-country rights and confidentiality, say Claire Phipps-Jones and Luke Norton of Bristows.
Americas
Companies that integrate data rights into their IP strategy with a holistic approach will lead in innovation while minimising risk, says Terri Shieh-Newton of Mintz.
Latest Conference Videos
Americas
Speakers from Greenberg Traurig, Verdiva Bio, Halozyme, and Metsera discuss the implications of the USPTO’s 2024 §112 guidelines on life sciences patents.
Europe
Amanda Simons, J A Kemp, explains how clinical research affects patentability in Europe and how clinical data can be used to strengthen protection.
Biotechnology
Dirk Buehler, Maiwald, discusses how the “try and see” standard is applied before the EPO and its relevance in pharma and biotech cases.
Europe
High-value IP disputes are reshaping life sciences litigation, with perspectives from McDermott Will & Emery, Curevac, Regeneron, HGF, and the UPC.
More News
9 April 2026 In light of Emotional Perception AI, the UKIPO has rewritten the rules for “mixed inventions". Matt Jefferies and Eric McNeil of Marks & Clerk explore what this pivot means for applicants protecting their AI technology.
9 April 2026 The firm has added two partners to its government and regulatory team, bringing expertise in FDA matters, product approvals, and regulatory risk.
8 April 2026 The acquisition of Munich-based biotech gives Gilead ownership of proprietary ADCs tech at a time when pharma and biotech companies are racing to secure next-generation cancer treatments.
7 April 2026 On World Health Day 2026, despite data trending in the right direction, systemic barriers continue to limit female inventors—and women's health is suffering.
7 April 2026 According to the settlement, MSN can maintain its challenge to several Bausch patents, while the details around potential product launch timings are unknown.
2 April 2026 Two of Europe’s most important IP offices have implemented fee increases this month, with some long-standing UK charges, dating back to the late 1990s, finally seeing a rise.
2 April 2026 A Lisbon judge rejects a bid to strike out the case over a drafting issue, offering insight into the court’s high bar for early dismissal.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox